

## Consolidated Financial Statements for the Nine Months Ended September 30, 2008

November 5, 2008

Company name **HORIBA, Ltd.**

Stock exchange listings: Tokyo, Osaka

Listing code 6856

URL: <http://www.horiba.co.jp>

Representative Atsushi Horiba, Chairman, President and CEO

Contact Fumitoshi Sato, Managing Director

TEL: (81)75-313-8121

(Figures have been rounded down to the nearest million yen.)

### 1. Consolidated Results for the Nine Months Ended September 30, 2008 (January 1, 2008 – September 30, 2008)

(1) Consolidated Operating Results (Percentages represent changes from the corresponding period in the previous year.)

	Net sales		Operating income		Ordinary income		Net income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Nine months ended 9/30/08	99,448	(1.5)	8,161	(29.2)	7,687	(31.8)	4,764	(11.2)
Nine months ended 9/30/07	100,964	—	11,531	—	11,265	—	5,367	—
Year ended 12/31/07	144,283		16,529		15,949		8,690	

	Net income per share	Net income per share (diluted)
	Yen	Yen
Nine months ended 9/30/08	112.61	112.54
Nine months ended 9/30/07	126.68	126.29
Year ended 12/31/07	205.01	204.39

As a result of a change in the fiscal year-end from March 20 to December 31, the accounting term for the Company and HORIBA Advanced Techno Co., Ltd. was only 9 months and 11 days and the one for HORIBA STEC, Co., Ltd. was only 9 months for the year ended December 31, 2006. Since the consolidated results for the nine months ended September 30, 2006 have not been announced, the year-to-year comparison for previous years are not presented in this report.

### (2) Consolidated Financial Position

	Total assets	Net assets	Shareholders' equity ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
As of 9/30/08	142,049	79,207	55.8	1,873.12
As of 9/30/07	149,057	76,877	51.6	1,812.21
As of 12/31/07	154,367	80,381	52.1	1,892.64

### (3) Consolidated Cash Flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Nine months ended 9/30/08	3,891	2,287	(2,609)	23,212
Nine months ended 9/30/07	7,194	(12,226)	10,305	20,964
Year ended 12/31/07	13,581	(16,444)	7,676	20,564

## 2. Dividends

(Base date)	Dividend per share		
	Interim	Year-end	Annual
Year ended 12/31/07	10.00 Yen	29.00 Yen	39.00 Yen
Year ending 12/31/08	15.00	25.00	40.00
Year ending 12/31/08 (Forecast)			

## 3. Consolidated Forecast for the Year Ending December 31, 2008 (January 1, 2008 – December 31, 2008) \*

(Percentages represent changes from the corresponding period in the previous year.)

	Net sales		Operating income		Ordinary income		Net income		Net income per share
Full year	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
	134,000	(7.1)	11,000	(33.5)	10,500	(34.2)	6,300	(27.5)	148.92

## 4. Others

- (1) Changes in scope of consolidation and application of the equity method during the Nine months ended September 30, 2008: None
- (2) Adoption of simplified methods in accounting policies: None
- (3) Changes in accounting policies from the latest fiscal year: Yes

(Note) For details, please refer to "4. Others" on page 6.

\* Taking into the current business performance, HORIBA, Ltd. revised the consolidated forecast of net sales, operating income, ordinary income and net income for the year ending December 31, 2008 announced on August 18, 2008, but the forecast of dividends was not changed. Please refer to "3. Outlook for the year ending December 31, 2008" on page 4. The forecast was computed based on the information available at November 5, 2008. Numerous uncertainties may cause the actual results to be materially different from the forecast.

## 1. Operating Results (Please refer to page 16 of financial highlights for the nine months ended September 30, 2008)

With regard to the operating results of HORIBA, Ltd., (“the Company”) and its consolidated subsidiaries (together “the HORIBA Group” or “HORIBA” as a consolidated group) during the nine months ended September 30, 2008 (the third quarter), sales fell in the semiconductor instruments and systems due to a sharp drop in investments in the semiconductor industry, while net sales increased significantly in the automotive test systems due to favorable growth in investments in development related to energy saving engines by auto manufacturers. As a result, despite a difficult business environment with an appreciating yen, net sales fell only slightly by 1.5% to 99,448 million yen from the corresponding nine months of previous year. As for income, mainly due to lower sales, deterioration of profits in the U.S. market resulting from decline of the dollar against the yen and euro up until July, and higher depreciation expenses following the commencement of operation of the new enterprise resource planning (“ERP”) system, operating income fell 29.2% to 8,161 million yen, and ordinary income also dropped 31.8% to 7,687 million yen from the corresponding nine months of previous year. As for net income, it fell slightly to 4,764 million yen, down 11.2% from the corresponding nine months of previous year, owing to improvement in our special gains/losses position.

Net sales generated in the first (January 1, 2008 through March 31, 2008) and the second quarter (April 1, 2008 through June 30, 2008) of the year ending December 31, 2008 were below those generated in the corresponding quarters of the year ending December 31, 2007 whereas net sales generated in the third quarter (July 1, 2008 through September 30, 2008) were higher mainly due to an increase of the sales in the automotive test systems. Accordingly, the decrease of operating income compared to the same quarter of previous year reduced in the third quarter compared with the decrease in the first quarter and in the second quarter. Please refer to “Consolidated Financial Results (Quarterly Comparison)” in the “Financial Highlights for the Nine Months Ended September 30, 2008” on page 17.

The operating results pertaining to each relevant business segment are summarized as follows:

### **(Automotive Test Systems)**

This business segment generated ¥38,457 million in net sales corresponding to a 15.8% increase compared to the same quarter of previous year. Operating income was ¥5,024 million corresponding to a 22.4% increase compared to the same quarter of previous year. Increase of net sales was mainly due to the sales of emission measurement systems, our mainstay, which remained strong in Japan and Europe, thanks to the accelerated developments in energy saving engines by auto manufacturers to counter the inflated price of crude oil and CO<sub>2</sub> regulation. The increase of operating income was mainly due to emission measurement systems sales development, despite the fact that the automotive test systems (DTS) business which was acquired from Germany’s Carl Schenck AG on September 30, 2005, incurred negative results.

### **(Analytical Instruments & Systems)**

This business segment generated ¥28,337 million in net sales, corresponding to a 0.8% decrease compared to the same quarter of previous year. Operating income was ¥1,346 million, corresponding to a 26.8% decrease compared to the same quarter of previous year. The decrease in net sales and in operating income was mainly due to the deceleration of capital investment in the private sector under global economic recession, sluggish overall demand and severe price competition.

### **(Medical/Diagnostic Instruments & Systems)**

This business segment generated ¥18,855 million in net sales, corresponding to a 1.7% increase compared to the same quarter of previous year. Operating income was ¥425 million corresponding to a 48.0% decrease compared to the same quarter of previous year. Increase in net sales was mainly due to expanded net sales of testing reagents due to growth in the number of analyzers in use. Decrease in operating income was mainly due to decreased profitability for small-size hematology analyzers manufactured in France and sold in Americas and Asia with an unfavorable exchange rate of the euro against the U.S. dollar for the first seven months.

### **(Semiconductor Instruments & Systems)**

This business segment generated ¥13,798 million in net sales, corresponding to a 33.2% decrease compared to the same quarter of previous year. Operating income was ¥1,364 million, corresponding to a 71.4% decrease compared to the same quarter of previous year. Decrease of net sales and operating income was mainly due to the fact that net sales of mass flow controllers used in semiconductor manufacturing equipment and chemical concentration monitors used in semiconductor cleaning equipment severely dropped in the sluggish semiconductor markets. In contrast, net sales of mass flow controllers used in solar cell manufacturing equipment increased mainly in European market.

## 2. Financial Condition

As of September 30, 2008, total assets amounted to ¥142,049 million, corresponding to a ¥12,317 million decrease compared to the balance established on December 31, 2007. The main factors explaining the decrease consist of a ¥2,859 million decrease in cash and bank deposits and a ¥8,203 million decrease in trade notes and accounts receivable.

Total liabilities amounted to ¥62,842 million, corresponding to a ¥11,143 million decrease compared to the balance established on December 31, 2007. The main factors explaining the decrease consist of a ¥4,275 million decrease in trade notes and accounts payable and a ¥5,000 million decrease in current maturities of corporate bonds.

Total net assets amounted to ¥79,207 million, corresponding to a ¥1,173 million decrease compared to the balance established on December 31, 2007. This evolution is mainly due to the payment of cash dividends and a decrease of foreign currency translation adjustments, partially offset by an increase in retained earnings reflecting net income.

The cash flow status for the nine months ended September 30, 2008 is as follows.

Cash and cash equivalents provided in operating activities amounted to ¥3,891 million. This was mainly due to a ¥7,792 million in income before income taxes, a ¥3,293 million in depreciation, and a ¥5,631 million decrease in trade notes and accounts receivable partially offset by ¥6,098 million for income taxes paid, a ¥3,254 million decrease in trade notes and accounts payable, and a ¥2,494 million increase in inventories.

Cash and cash equivalents provided in investing activities totaled ¥2,287 million. This was mainly due to a ¥7,512 million decrease in time deposits partially offset by ¥3,939 million in payments for the purchase of property, plant and equipment and ¥943 million in payments for the purchase of intangibles.

Cash and cash equivalents used by financing activities amounted to ¥2,609 million. This was mainly due to a ¥5,000 million payment for redemption of corporate bonds, a ¥1,852 million payment for cash dividends and a ¥800 million payments for the purchase of treasury stock partially offset by a ¥4,471 million increase in short-term borrowings.

As a result, cash and cash equivalents at September 30, 2008 increased by a ¥2,647 million and amounted to ¥23,212 million.

## 3. Outlook for the year ending December 31, 2008

Below is an outlook for the year ending December 31, 2008.

### Outlook for the year ending December 31, 2008

(Unit: millions of yen)

	Previous forecast (As of Aug.18)	Revised forecast (As of Nov. 5)	Changes
Net sales	141,000	134,000	-7,000
Operating income	11,500	11,000	-500
Ordinary income	11,000	10,500	-500
Net income	6,600	6,300	-300

### By business segment

Net sales (Unit: millions of yen)

	Previous forecast (As of Aug.18)	Revised forecast (As of Nov. 5)	Changes
Automotive	55,500	53,000	-2,500
Analytical	40,000	38,000	-2,000
Medical	26,500	25,000	-1,500
Semiconductor	19,000	18,000	-1,000
Total	141,000	134,000	-7,000

Operating income (Unit: millions of yen)

	Previous forecast (As of Aug.18)	Revised forecast (As of Nov. 5)	Changes
Automotive	6,200	6,700	+500
Analytical	2,300	2,000	-300
Medical	700	900	+200
Semiconductor	2,300	1,400	-900
Total	11,500	11,000	-500

Taking into consideration the business performance during the nine months ended September 30, 2008, the effect of exchange rate and the level of market demand during the fourth quarter (October 1, 2008 through December 31, 2008), the forecasted net sales incurred a ¥7,000 million decrease compared to the previous forecast.

Due to the decrease of net sales, operating and ordinary income incurred a ¥500 million drop respectively whereas net income incurred a ¥300 million reduction compared to previous forecast despite our continuing effort to reduce costs and implement various measures to enhance profitability.

The outlook for the year ending December 31, 2008 by business segment is summarized as follows:

#### **(Automotive Test Systems)**

In the revised forecast, net sales in this business segment decreased by ¥2,500 million compared with the previous forecast. This was mainly due to the conversion in yen of net sales originally computed in euros.

As for income, operating income increased by ¥500 million compared with the previous forecast. This was mainly due to an increase sale of emission measurement systems units, our mainstay, driven by a continuous strong market demand.

#### **(Analytical Instruments & Systems)**

In the revised forecast, net sales and operating income in this business segment decreased by ¥2,000 million and by ¥300 million, respectively, compared with the previous forecast. The decreases were mainly due to decreases of net sales and profit margin under the negative effect of the higher appreciation of the yen.

#### **(Medical/Diagnostic Instruments & Systems)**

In the revised forecast, net sales in this business segment decreased by ¥1,500 million compared with the previous forecast. This was mainly due to the conversion in yen of net sales originally computed in euros. As for income, operating income increased by ¥200 million compared with the previous forecast. This was mainly due to the improvement in profitability of export from Europe to other regions pursuant to recent weakened euro.

#### **(Semiconductor Instruments & Systems)**

In the revised forecast, net sales in this business segment decreased by ¥1,000 million and operating income decreased by ¥900 million compared with the previous forecast. Decreases were mainly due to demand decline and a fall of selling price while the business environment of semiconductor market got worse than expected in the previous forecast.

There is no change in the non-consolidated previous forecast which we announced on August 18, 2008.

The Company has a policy of maintaining a standard payout ratio in which the total dividend payment amount is equal to 30% of the non-consolidated net income.

Consequently there is no change in the previous forecast of the dividend for the year ending December 31, 2008.

#### **\*Mid-Long Term Management Plan**

HORIBA had started to draw up a new mid-long term management plan this year following the business results were ahead of the present mid-long term management plan, which will end in the fiscal year ending December 31, 2010, in the first two years.

However, a recent worldwide depression stemming from the sub-prime crisis in the US and fluctuations in currency exchange rates brought a substantial level of uncertainty in our future business environment.

Considering such an unpredictable economical context, HORIBA has decided to suspend the establishment of a new mid-long term management plan in the near future and better concentrate on completing the present plan.

HORIBA remains confident that investors will understand its decision to suspend, for the time being, the launch of a new mid-long term management plan.

\*The forecast was computed based on the information available at November 5, 2008. Numerous uncertainties may cause the actual results to be materially different from the forecast. Of uncertainties, some of the main factors are listed as follows.

**Business risks:**

Risks associated with international business activities including a loss from fluctuation of currency exchange rates, changes in performance or financial position associated with acquisitions or alliances, repairs of facilities following natural disasters and associated delays in delivery, etc., risks associated with contract and transaction, laws and regulations, other business risks

**Risks associated with development and production:**

Compensation for product liability, delays in development of new products, risks concerning intellectual property rights, risks concerning fluctuation in raw material prices

**Financial risks:**

Shifts in the market price of securities holding or other assets, reversal of deferred tax assets resulting from changes in systems or accounting policies

#### 4. Others

**(1) Changes in scope of consolidation and application of the equity method during the nine months ended September 30, 2008:**

None

**(2) Adoption of simplified methods in accounting policies:**

None

**(3) Changes in accounting policies from the latest fiscal year:**

**(Depreciation of fixed assets)**

Effective January 1, 2008, the Company and its domestic subsidiaries adopted the method of depreciation for fixed assets acquired on or after April 1, 2007 provided by the revised Corporate Tax Law, following the completion of its fixed assets management system. As a result of this change, operating income, ordinary income and income before income taxes were ¥101 million less, respectively, than they would have been without the adoption of the new method. The effect of this change per business segment was mentioned in "Segment Information".

**<Additional information>**

The Company and its domestic subsidiaries adopted the revised Corporation Tax Law and changed its method of depreciation of tangible fixed assets acquired on or before March 31, 2007. Accordingly, the difference between the residual value of such an asset and the value equivalent to 5% of its acquisition cost, as computed by the previous Corporation Tax Law, is depreciated over a period of five years starting from the year following the year in which the value of the asset falls to 5% of its acquisition cost. The difference is amortized by the straight-line method and is included in depreciation expense. This change did not have a material impact on operating income, ordinary income, or income before income taxes.

**(Loss on the disposal of inventories and the write-down of inventories)**

Effective January 1, 2008, the Company and certain of its domestic subsidiaries reclassified loss on the disposal of inventories and loss on the write-down of inventories from non-operating expense to cost of sales in connection with changes in management and organizational structure to cope with the increased number of the titles relating to publications and the necessities of cost management. This change did not have a material impact on the results of operating income and did not have any impact on ordinary income or income before income taxes.

**(Foreign currency forward contracts)**

Prior to January 1, 2008, assets and liabilities denominated in foreign currencies that were hedged by foreign currency forward contracts were translated at the contracted rates if the forward contracts qualified for hedge accounting. Effective January 1, 2008, the Company and its domestic subsidiaries changed this method of accounting for such hedge activities. Under the new policy, foreign currency forward contracts used to hedge foreign exchange exposure are measured at fair value and the unrealized gains (losses) are recognized in income. This change did not have any impact on the results of operating income and did not have a material impact on ordinary income or income before income taxes.

## 5. Consolidated Financial Statements

### (1) Consolidated Balance Sheets

Accounts	As of September 30, 2007		As of September 30, 2008		Increase (Decrease)		As of December 31, 2007	
	Amount	%	Amount	%	Amount	%	Amount	%
<b>Assets</b>	Millions of yen		Millions of yen		Millions of yen		Millions of yen	
<b>Current Assets:</b>	108,344	72.7	101,102	71.2	(7,242)	(6.7)	113,330	73.4
Cash and bank deposits	23,235		19,204		(4,030)		22,064	
Trade notes and accounts receivable	41,774		37,668		(4,105)		45,872	
Marketable securities	3,430		4,707		1,277		6,710	
Inventories	35,327		34,206		(1,121)		33,734	
Deferred tax assets	2,737		2,668		(69)		2,781	
Other current assets	2,852		3,357		504		2,731	
Allowance for doubtful receivables	(1,014)		(710)		303		(564)	
<b>Fixed Assets:</b>	40,712	27.3	40,946	28.8	234	0.6	41,037	26.6
<b>Property, Plant and Equipment:</b>	23,727	15.9	24,143	17.0	416	1.8	24,070	15.6
Buildings and structures	7,952		7,193		(758)		7,903	
Machinery, equipment, and vehicles	4,279		4,100		(178)		4,342	
Land	7,478		7,432		(45)		7,525	
Construction in progress	1,551		2,107		555		644	
Other property, plant and equipment	2,465		3,308		843		3,654	
<b>Intangibles:</b>	8,132	5.5	7,899	5.5	(232)	(2.9)	8,502	5.5
Goodwill	1,223		709		(514)		1,077	
Other intangibles	6,908		7,190		282		7,424	
<b>Investments and Other Non-Current Assets:</b>	8,852	5.9	8,903	6.3	50	0.6	8,464	5.5
Investment securities	5,035		3,969		(1,066)		4,759	
Deferred tax assets	1,198		2,346		1,147		1,345	
Other investments and other assets	2,704		2,680		(24)		2,678	
Allowance for doubtful accounts	(86)		(92)		(6)		(320)	
<b>Total Assets</b>	149,057	100.0	142,049	100.0	(7,007)	(4.7)	154,367	100.0

Accounts	As of September 30, 2007		As of September 30, 2008		Increase (Decrease)		As of December 31, 2007	
	Amount	%	Amount	%	Amount	%	Amount	%
Liabilities	Millions of yen		Millions of yen		Millions of yen		Millions of yen	
Current Liabilities:	56,574	37.9	47,082	33.1	(9,491)	(16.8)	58,038	37.6
Trade notes and accounts payable	15,444		12,569		(2,875)		16,845	
Short-term loans payable	10,261		11,186		924		7,540	
Current maturities of corporate bonds	5,000		–		(5,000)		5,000	
Accounts payable – other	10,444		9,650		(794)		12,525	
Accrued income taxes	2,817		1,249		(1,568)		3,795	
Deferred tax liabilities	1		4		3		42	
Accrued bonuses to employees	1,537		1,422		(114)		703	
Accrued bonuses to directors and corporate auditors	362		378		15		119	
Reserve for product warranty	1,103		980		(123)		1,148	
Provision for possible losses from litigation	1,204		1,204		–		1,204	
Other current liabilities	8,397		8,437		40		9,112	
Non-Current Liabilities:	15,604	10.5	15,759	11.1	154	1.0	15,947	10.3
Corporate bonds	10,000		10,000		–		10,000	
Long-term debt	2,584		2,632		48		2,637	
Deferred tax liabilities	0		130		130		205	
Employees' retirement benefits	1,680		1,587		(92)		1,813	
Directors' and corporate auditors' retirement benefits	691		763		71		709	
Reserve for loss on guarantees	52		52		–		52	
Other non-current liabilities	596		592		(3)		529	
Total Liabilities	72,179	48.4	62,842	44.2	(9,337)	(12.9)	73,985	47.9
Net Assets								
Shareholders' Equity	72,484	48.6	78,173	55.1	5,689	7.8	75,967	49.2
Common stock	11,872	8.0	12,006	8.5	134	1.1	11,952	7.7
Capital surplus	18,578	12.4	18,712	13.2	134	0.7	18,658	12.1
Retained earnings	42,042	28.2	48,264	34.0	6,221	14.8	45,365	29.4
Treasury stock	(9)	(0.0)	(810)	(0.6)	(801)	–	(9)	(0.0)
Valuation and Translation Adjustments	4,390	3.0	1,029	0.7	(3,361)	(76.5)	4,410	2.9
Net unrealized holding gains on securities	1,780	1.2	859	0.6	(920)	(51.7)	1,621	1.1
Foreign currency translation adjustments	2,610	1.8	169	0.1	(2,440)	(93.5)	2,788	1.8
Minority Interests in Consolidated Subsidiaries	2	0.0	4	0.0	1	62.7	3	0.0
Total Net Assets	76,877	51.6	79,207	55.8	2,330	3.0	80,381	52.1
Total Liabilities and Net Assets	149,057	100.0	142,049	100.0	(7,007)	(4.7)	154,367	100.0



(2) Consolidated Statements of Income

Accounts	Nine Months Ended September 30, 2007		Nine Months Ended September 30, 2008		Increase (Decrease)		Year Ended December 31, 2007	
	Amount	%	Amount	%	Amount	%	Amount	%
Net Sales	100,964	100.0	99,448	100.0	(1,516)	(1.5)	144,283	100.0
Cost of Sales	53,475	53.0	54,226	54.5	751	1.4	77,364	53.6
<b>Gross Income</b>	<b>47,489</b>	<b>47.0</b>	<b>45,221</b>	<b>45.5</b>	<b>(2,268)</b>	<b>(4.8)</b>	<b>66,918</b>	<b>46.4</b>
Selling, General and Administrative Expenses	35,958	35.6	37,060	37.3	1,102	3.1	50,388	34.9
<b>Operating Income</b>	<b>11,531</b>	<b>11.4</b>	<b>8,161</b>	<b>8.2</b>	<b>(3,370)</b>	<b>(29.2)</b>	<b>16,529</b>	<b>11.5</b>
Other Income	760	0.8	655	0.6	(104)	(13.8)	998	0.7
Interest income	168		265		96		246	
Dividend income	53		69		15		85	
Other	537		320		(217)		666	
Other Expenses	1,026	1.0	1,129	1.1	102	10.0	1,578	1.1
Interest expense	563		689		125		796	
Foreign exchange losses	241		231		(9)		320	
Loss on write-down of inventories	40		–		(40)		48	
Loss on disposal of inventories	13		–		(13)		51	
Other	166		208		42		361	
<b>Ordinary Income</b>	<b>11,265</b>	<b>11.2</b>	<b>7,687</b>	<b>7.7</b>	<b>(3,578)</b>	<b>(31.8)</b>	<b>15,949</b>	<b>11.1</b>
Special Gains	20	0.0	275	0.3	255	–	26	0.0
Gain on sale of property, plant and equipment	20		15		(5)		26	
Gain on insurance surrender value	–		253		253		–	
Other	–		6		6		–	
Special Losses	1,843	1.8	170	0.2	(1,672)	(90.7)	1,870	1.3
Loss on disposal of property, plant and equipment	35		29		(5)		53	
Loss on sale of property, plant and equipment	12		8		(3)		19	
Provision for possible losses from litigation	1,041		–		(1,041)		1,041	
Loss due to changes in accounting policies	703		–		(703)		703	
Reserve for loss on guarantees	52		–		(52)		52	
Loss on reorganization of U.S. subsidiaries	–		132		132		–	
Other	0		–		(0)		0	
<b>Income Before Income Taxes</b>	<b>9,442</b>	<b>9.4</b>	<b>7,792</b>	<b>7.8</b>	<b>(1,650)</b>	<b>(17.5)</b>	<b>14,105</b>	<b>9.8</b>
Income taxes (current)	5,121	5.1	3,656	3.6	(1,464)	(28.6)	6,603	4.6
Income taxes (deferred)	(1,045)	(1.0)	(630)	(0.6)	415	–	(1,184)	(0.8)
Minority interests in earnings of consolidated subsidiaries	(1)	(0.0)	1	0.0	2	–	(3)	(0.0)
<b>Net Income</b>	<b>5,367</b>	<b>5.3</b>	<b>4,764</b>	<b>4.8</b>	<b>(603)</b>	<b>(11.2)</b>	<b>8,690</b>	<b>6.0</b>

### (3) Consolidated Statements of Changes in Shareholders' Equity

Nine Months Ended September 30, 2007 (January 1, 2007 – September 30, 2007)

	Shareholders' equity				
	Common stock	Capital surplus	Retained earnings	Treasury stock	Total shareholders' equity
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Balance at December 31, 2006	11,738	18,444	37,864	(18)	68,029
Changes during the fiscal period					
Issuance of new shares (Exercise of stock acquisition rights)	133	133			267
Cash dividends			(1,185)		(1,185)
Net income			5,367		5,367
Acquisition of treasury stocks				(1)	(1)
Disposal of treasury stocks			(4)	10	5
Others					
Total changes during the fiscal period	133	133	4,178	8	4,454
Balance at September 30, 2007	11,872	18,578	42,042	(9)	72,484

  

	Valuation and translation adjustments			Minority Interests	Total Net Assets
	Net unrealized holding gains on securities	Foreign currency translation adjustments	Total valuation and translation adjustments		
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Balance at December 31, 2006	2,090	2,251	4,341	3	72,375
Changes during the fiscal period					
Issuance of new shares (Exercise of stock acquisition rights)					267
Cash dividends					(1,185)
Net income					5,367
Acquisition of treasury stocks					(1)
Disposal of treasury stocks					5
Others	(310)	359	49	(1)	47
Total changes during the fiscal period	(310)	359	49	(1)	4,502
Balance at September 30, 2007	1,780	2,610	4,390	2	76,877

Nine Months Ended September 30, 2008 (January 1, 2008 – September 30, 2008)

	Shareholders' equity				
	Common stock	Capital surplus	Retained earnings	Treasury stock	Total shareholders' equity
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Balance at December 31, 2007	11,952	18,658	45,365	(9)	75,967
Changes during the fiscal period					
Issuance of new shares (Exercise of stock acquisition rights)	54	54			108
Cash dividends			(1,865)		(1,865)
Net income			4,764		4,764
Acquisition of treasury stocks				(800)	(800)
Others					
Total changes during the fiscal period	54	54	2,898	(800)	2,206
Balance at September 30, 2008	12,006	18,712	48,264	(810)	78,173

  

	Valuation and translation adjustments			Minority Interests	Total Net Assets
	Net unrealized holding gains on securities	Foreign currency translation adjustments	Total valuation and translation adjustments		
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Balance at December 31, 2007	1,621	2,788	4,410	3	80,381
Changes during the fiscal period					
Issuance of new shares (Exercise of stock acquisition rights)					108
Cash dividends					(1,865)
Net income					4,764
Acquisition of treasury stocks					(800)
Others	(761)	(2,618)	(3,380)	0	(3,380)
Total changes during the fiscal period	(761)	(2,618)	(3,380)	0	(1,173)
Balance at September 30, 2008	859	169	1,029	4	79,207

Year Ended December 31, 2007 (January 1, 2007 – December 31, 2007)

	Shareholders' equity				
	Common stock	Capital surplus	Retained earnings	Treasury stock	Total shareholders' equity
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Balance at December 31, 2006	11,738	18,444	37,864	(18)	68,029
Changes during the fiscal year					
Issuance of new shares (Exercise of stock acquisition rights)	214	214			428
Cash dividends			(761)		(761)
Cash dividends (Interim dividend)			(423)		(423)
Net income			8,690		8,690
Acquisition of treasury stocks				(1)	(1)
Disposal of treasury stocks			(4)	10	5
Others					
Total changes during the fiscal year	214	214	7,500	8	7,937
Balance at December 31, 2007	11,952	18,658	45,365	(9)	75,967

	Valuation and translation adjustments			Minority Interests	Total Net Assets
	Net unrealized holding gains on securities	Foreign currency translation adjustments	Total valuation and translation adjustments		
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Balance at December 31, 2006	2,090	2,251	4,341	3	72,375
Changes during the fiscal year					
Issuance of new shares (Exercise of stock acquisition rights)					428
Cash dividends					(761)
Cash dividends (Interim dividend)					(423)
Net income					8,690
Acquisition of treasury stocks					(1)
Disposal of treasury stocks					5
Others	(468)	537	68	(0)	68
Total changes during the fiscal year	(468)	537	68	(0)	8,006
Balance at December 31, 2007	1,621	2,788	4,410	3	80,381

## (4) Consolidated Statements of Cash Flows

Accounts	Nine Months Ended September 30, 2007	Nine Months Ended September 30, 2008	Year Ended December 31, 2007
	Millions of yen	Millions of yen	Millions of yen
<b>Cash Flows from Operating Activities:</b>			
Income before income taxes	9,442	7,792	14,105
Depreciation (excludes amortization of goodwill)	2,479	3,293	3,671
Amortization of goodwill	379	382	489
Increase (decrease) in allowance for doubtful receivables	62	(2)	(163)
Increase in provision for possible losses from litigation	1,204	-	1,204
Increase (decrease) in employees' retirement benefits	25	(61)	149
Increase (decrease) in directors' and corporate auditors' retirement benefits	32	53	50
Increase in reserve for loss on guarantees	52	-	52
Interest and dividend income	(222)	(334)	(331)
Interest expense	563	689	796
Bond issuance costs	55	-	55
Foreign exchange losses (gains)	36	(37)	65
Gain on sale of property, plant and equipment	(20)	(15)	(26)
Loss on disposal of property, plant and equipment	34	29	53
Loss on sale of property, plant and equipment	12	8	19
Loss due to changes in accounting policies	703	-	703
Decrease (increase) in trade notes and accounts receivable	1,320	5,631	(2,432)
Decrease (increase) in inventories	(4,623)	(2,494)	(2,830)
Increase (decrease) in trade notes and accounts payable	(179)	(3,254)	610
Other, net	544	(1,311)	2,857
<b>Subtotal</b>	11,902	10,368	19,100
Interest and dividends received	230	355	312
Interest paid	(543)	(733)	(672)
Income taxes paid	(4,394)	(6,098)	(5,157)
<b>Net cash provided by operating activities</b>	7,194	3,891	13,581
<b>Cash Flows from Investing Activities:</b>			
Increase in time deposits	(5,000)	(5)	(7,508)
Decrease in time deposits	1	7,512	1
Increase in time deposits restricted for use	(700)	-	(700)
Payments for purchase of property, plant and equipment	(4,503)	(3,939)	(5,700)
Proceeds from sale of property, plant and equipment	635	207	820
Payments for purchase of intangibles	(2,472)	(943)	(3,400)
Payments for purchase of investment securities	(10)	(512)	(14)
Proceeds from sale or redemption of investment securities	6	-	7
Increase in loans receivable	(182)	(1)	(17)
Decrease in loans receivable	38	11	81
Other, net	(39)	(42)	(14)
<b>Net cash used in investing activities</b>	(12,226)	2,287	(16,444)
<b>Cash Flows from Financing Activities:</b>			
Payment for redemption of corporate bonds	-	(5,000)	-
Net increase (decrease) in short-term borrowings	1,054	4,471	(1,758)
Increase in long-term debt	802	1,109	1,015
Repayment of long-term debt	(569)	(643)	(753)
Proceeds from issuance of bonds	9,944	-	9,944
Proceeds from exercise of stock acquisition rights	267	108	428
Payments for purchase of treasury stock	(1)	(800)	(1)
Proceeds from sale of treasury stock	5	-	5
Cash dividends paid	(1,189)	(1,852)	(1,192)
Other, net	(8)	(1)	(11)
<b>Net cash provided by financing activities</b>	10,305	(2,609)	7,676
<b>Effect of Exchange Rate Changes on Cash and Cash Equivalents</b>	18	(922)	78
<b>Net Increase (Decrease) in Cash and Cash Equivalents</b>	5,291	2,647	4,892
<b>Cash and Cash Equivalents at Beginning of Period</b>	15,672	20,564	15,672
<b>Cash and Cash Equivalents at End of Period</b>	20,964	23,212	20,564

## 5. Segment Information

[Business Segment Information]

Nine Months Ended September 30, 2007 (January 1, 2007 – September 30, 2007)

Millions of yen

	Automotive Test Systems	Analytical Instruments & Systems	Medical/Diagnostic Instruments & Systems	Semiconductor Instruments & Systems	Total	Elimination and/or unallocated	Consolidated
<b>Net Sales</b>							
(1) Sales to outside customers	33,222	28,554	18,533	20,654	100,964	—	100,964
(2) Intersegment sales and transfers	—	—	—	—	—	—	—
Total	33,222	28,554	18,533	20,654	100,964	—	100,964
Operating Expenses	29,117	26,715	17,713	15,886	89,433	—	89,433
<b>Operating Income</b>	4,105	1,838	819	4,767	11,531	—	11,531

Nine Months Ended September 30, 2008 (January 1, 2008 – September 30, 2008)

Millions of yen

	Automotive Test Systems	Analytical Instruments & Systems	Medical/Diagnostic Instruments & Systems	Semiconductor Instruments & Systems	Total	Elimination and/or unallocated	Consolidated
<b>Net Sales</b>							
(1) Sales to outside customers	38,457	28,337	18,855	13,798	99,448	—	99,448
(2) Intersegment sales and transfers	—	—	—	—	—	—	—
Total	38,457	28,337	18,855	13,798	99,448	—	99,448
Operating Expenses	33,433	26,991	18,429	12,433	91,287	—	91,287
<b>Operating Income</b>	5,024	1,346	425	1,364	8,161	—	8,161

(Note)

(Change in Accounting Standards)

As shown in Note "4. Other, (3) Changes in accounting policies from the latest fiscal year (Depreciation of fixed assets)," the Company and its domestic subsidiaries adopted the method of depreciation for fixed assets acquired on or after April 1, 2007 provided by the revised Corporate Tax Law. As a result, operating expenses were ¥38 million more in Automotive Test Systems, ¥36 million more in Analytical Instruments & Systems, ¥4 million more in Medical/Diagnostic Instruments & Systems and ¥21 million more in Semiconductor Instruments & Systems than they would have been without the adoption of the new method. Operating income was less by the same amounts accordingly.

Year Ended December 31, 2007 (January 1, 2007 – December 31, 2007)

Millions of yen

	Automotive Test Systems	Analytical Instruments & Systems	Medical/Diagnostic Instruments & Systems	Semiconductor Instruments & Systems	Total	Elimination and/or unallocated	Consolidated
<b>Net Sales</b>							
(1) Sales to outside customers	51,475	40,038	25,835	26,934	144,283	—	144,283
(2) Intersegment sales and transfers	—	—	—	—	—	—	—
Total	51,475	40,038	25,835	26,934	144,283	—	144,283
Operating Expenses	44,717	37,366	24,603	21,066	127,753	—	127,753
<b>Operating Income</b>	6,757	2,672	1,232	5,867	16,529	—	16,529

Main Products in Each Business Segment

Business Segment	Main Products
Automotive Test Systems	Emission Measurement Systems, In-Use Automotive Emissions Analyzers, On-Board Emission Measurement Systems, Fuel Cell Evaluation Systems, Driveline Test Systems, Engine Test Systems, Brake Test Systems, Drive Recorders
Analytical Instruments & Systems	Scientific Analysis Instruments (Particle-size Distribution Analyzers, X-ray Fluorescence Analyzers, Raman Spectrophotometers, Diffraction, Gratings) Environmental Measuring Instruments (pH Meters, Stack Gas Analyzers, Water Quality Analysis and Examination Systems, Air Pollution Analyzers)
Medical/Diagnostic Instruments & Systems	Equipment for Blood Sample Analysis (Hematology Analyzers, Equipment for Measuring Immunological Responses, Clinical Chemistry Analyzers, Blood Sugar Measurement Systems)
Semiconductor Instruments & Systems	Mass Flow Controllers, Chemical Concentration Monitors, Thin-film Analyzers for Semiconductors and LCD Inspection, Reticle/Mask Particle Detection Systems, Residual Gas Analyzers, Vacuum Meters

[Geographic Segment Information]

Nine Months Ended September 30, 2007 (January 1, 2007 – September 30, 2007)

Millions of yen

	Japan	Americas	Europe	Asia	Total	Elimination and/or unallocated	Consolidated
<b>Net Sales</b>							
(1) Sales to outside customers	46,043	12,581	38,712	3,627	100,964	—	100,964
(2) Intersegment sales and transfers	11,911	577	3,235	1,455	17,179	(17,179)	—
Total	57,955	13,159	41,947	5,082	118,144	(17,179)	100,964
Operating Expenses	47,117	12,893	41,939	4,445	106,396	(16,962)	89,433
<b>Operating Income</b>	10,837	265	8	637	11,748	(216)	11,531

Nine Months Ended September 30, 2008 (January 1, 2008 – September 30, 2008)

Millions of yen

	Japan	Americas	Europe	Asia	Total	Elimination and/or unallocated	Consolidated
<b>Net Sales</b>							
(1) Sales to outside customers	42,046	14,721	39,249	3,430	99,448	—	99,448
(2) Intersegment sales and transfers	10,709	1,183	3,313	1,565	16,770	(16,770)	—
Total	52,755	15,904	42,562	4,995	116,219	(16,770)	99,448
Operating Expenses	45,910	15,954	41,923	4,569	108,358	(17,071)	91,287
<b>Operating Income (Loss)</b>	6,845	(49)	639	426	7,860	300	8,161

(Note)

(Change in Accounting Standards)

As shown in Note "4. Other, (3) Changes in accounting policies from the latest fiscal year (Depreciation of fixed assets)," the Company and its domestic subsidiaries adopted the method of depreciation for fixed assets acquired on or after April 1, 2007 provided by the revised Corporate Tax Law. As a result, operating expenses were ¥101 million more, and operating income ¥101 million less in the Japan segment

Year Ended December 31, 2007 (January 1, 2007 – December 31, 2007)

Millions of yen

	Japan	Americas	Europe	Asia	Total	Elimination and/or unallocated	Consolidated
<b>Net Sales</b>							
(1) Sales to outside customers	61,707	18,556	58,972	5,046	144,283	—	144,283
(2) Intersegment sales and transfers	16,334	858	4,192	2,146	23,531	(23,531)	—
Total	78,042	19,415	63,164	7,192	167,815	(23,531)	144,283
Operating Expenses	65,117	18,355	61,323	6,321	151,117	(23,364)	127,753
<b>Operating Income</b>	12,924	1,060	1,840	871	16,697	(167)	16,529

[Overseas Sales]

Nine Months Ended September 30, 2007 (January 1, 2007 – September 30, 2007)

Millions of yen

	Americas	Europe	Asia	Total
Overseas sales	20,655	27,395	13,809	61,860
Consolidated sales	—	—	—	100,964
Ratio of overseas sales to consolidated sales (%)	20.5	27.1	13.7	61.3

(Note) Overseas sales comprise sales of the Company and its subsidiaries in countries or regions other than Japan.

Nine Months Ended September 30, 2008 (January 1, 2008 – September 30, 2008)

Millions of yen

	Americas	Europe	Asia	Total
Overseas sales	18,047	30,805	14,321	63,174
Consolidated sales	—	—	—	99,448
Ratio of overseas sales to consolidated sales (%)	18.1	31.0	14.4	63.5

(Note) Overseas sales comprise sales of the Company and its subsidiaries in countries or regions other than Japan.

Year Ended December 31, 2007 (January 1, 2007 – December 31, 2007)

Millions of yen

	Americas	Europe	Asia	Total
Overseas sales	29,780	41,947	20,585	92,313
Consolidated sales	—	—	—	144,283
Ratio of overseas sales to consolidated sales (%)	20.6	29.1	14.3	64.0

(Note) Overseas sales comprise sales of the Company and its subsidiaries in countries or regions other than Japan.

## 6. Others

### HORIBA, Ltd. Financial Highlights for the Nine Months Ended September 30, 2008

#### 1. Consolidated Financial Results

	12/2008 Result		12/2007 Result		Changes		12/2008 Estimate		12/2007 Result		Changes	
	3Q(9 months)	3Q(9 months)	3Q(9 months)	3Q(9 months)	Amount	Ratio	Full year	Full year	Full year	Full year	Amount	Ratio
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Net Sales	<b>99,448</b>	100,964	-1,516	-1.5%			<b>134,000</b>	144,283	-10,283	-7.1%		
Operating Income	<b>8,161</b>	11,531	-3,370	-29.2%			<b>11,000</b>	16,529	-5,529	-33.5%		
<i>Operating Income Ratio</i>	<b>8.2%</b>	11.4%	-3.2P				<b>8.2%</b>	11.5%	-3.2P			
Ordinary Income	<b>7,687</b>	11,265	-3,578	-31.8%			<b>10,500</b>	15,949	-5,449	-34.2%		
<i>Ordinary Income Ratio</i>	<b>7.7%</b>	11.2%	-3.4P				<b>7.8%</b>	11.1%	-3.2P			
Net Income	<b>4,764</b>	5,367	-603	-11.2%			<b>6,300</b>	8,690	-2,390	-27.5%		
<i>Net Income Ratio</i>	<b>4.8%</b>	5.3%	-0.5P				<b>4.7%</b>	6.0%	-1.3P			
US\$	<b>105.84</b>	119.41	-13.57				<b>103.00</b>	117.85	-14.85			
Euro	<b>161.14</b>	160.43	+0.71				<b>152.00</b>	161.31	-9.31			

#### 2. Consolidated Segment Results

	12/2008 Result		12/2007 Result		Changes		12/2008 Estimate		12/2007 Result		Changes	
	3Q(9 months)	3Q(9 months)	3Q(9 months)	3Q(9 months)	Amount	Ratio	Full year	Full year	Full year	Full year	Amount	Ratio
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Net Sales	<b>99,448</b>	100,964	-1,516	-1.5%			<b>134,000</b>	144,283	-10,283	-7.1%		
Automotive	<b>38,457</b>	33,222	+5,234	+15.8%			<b>53,000</b>	51,475	+1,524	+3.0%		
Analytical	<b>28,337</b>	28,554	-217	-0.8%			<b>38,000</b>	40,038	-2,038	-5.1%		
Medical	<b>18,855</b>	18,533	+321	+1.7%			<b>25,000</b>	25,835	-835	-3.2%		
Semiconductor	<b>13,798</b>	20,654	-6,856	-33.2%			<b>18,000</b>	26,934	-8,934	-33.2%		
Total	<b>99,448</b>	100,964	-1,516	-1.5%			<b>134,000</b>	144,283	-10,283	-7.1%		
Operating Income	<b>8,161</b>	11,531	-3,370	-29.2%			<b>11,000</b>	16,529	-5,529	-33.5%		
Automotive	<b>5,024</b>	4,105	+918	+22.4%			<b>6,700</b>	6,757	-57	-0.9%		
Analytical	<b>1,346</b>	1,838	-492	-26.8%			<b>2,000</b>	2,672	-672	-25.2%		
Medical	<b>425</b>	819	-393	-48.0%			<b>900</b>	1,232	-332	-26.9%		
Semiconductor	<b>1,364</b>	4,767	-3,402	-71.4%			<b>1,400</b>	5,867	-4,467	-76.1%		
Total	<b>8,161</b>	11,531	-3,370	-29.2%			<b>11,000</b>	16,529	-5,529	-33.5%		

#### 3. Consolidated Segment Sales by Region

	12/2008 Result		12/2007 Result		Changes		12/2008 Estimate		12/2007 Result		Changes	
	3Q(9 months)	3Q(9 months)	3Q(9 months)	3Q(9 months)	Amount	Ratio	Full year	Full year	Full year	Full year	Amount	Ratio
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Automotive	<b>38,457</b>	33,222	+5,234	+15.8%			<b>53,000</b>	51,475	+1,524	+3.0%		
Japan	<b>14,020</b>	11,688	+2,331	+19.9%			<b>18,000</b>	15,959	+2,040	+12.8%		
Asia	<b>5,681</b>	5,003	+678	+13.6%			<b>7,500</b>	8,059	-559	-6.9%		
Americas	<b>5,853</b>	6,531	-678	-10.4%			<b>8,500</b>	10,536	-2,036	-19.3%		
Europe	<b>12,902</b>	9,998	+2,903	+29.0%			<b>19,000</b>	16,920	+2,079	+12.3%		
Analytical	<b>28,337</b>	28,554	-217	-0.8%			<b>38,000</b>	40,038	-2,038	-5.1%		
Japan	<b>11,993</b>	11,706	+287	+2.5%			<b>17,000</b>	15,423	+1,576	+10.2%		
Asia	<b>4,754</b>	4,809	-54	-1.1%			<b>5,000</b>	6,957	-1,957	-28.1%		
Americas	<b>4,547</b>	4,957	-409	-8.3%			<b>6,500</b>	6,972	-472	-6.8%		
Europe	<b>7,041</b>	7,081	-39	-0.6%			<b>9,500</b>	10,684	-1,184	-11.1%		
Medical	<b>18,855</b>	18,533	+321	+1.7%			<b>25,000</b>	25,835	-835	-3.2%		
Japan	<b>2,799</b>	2,942	-143	-4.9%			<b>4,100</b>	4,043	+56	+1.4%		
Asia	<b>1,262</b>	1,282	-20	-1.6%			<b>1,800</b>	1,866	-66	-3.6%		
Americas	<b>5,226</b>	5,026	+200	+4.0%			<b>6,600</b>	7,033	-433	-6.2%		
Europe	<b>9,566</b>	9,281	+285	+3.1%			<b>12,500</b>	12,891	-391	-3.0%		
Semiconductor	<b>13,798</b>	20,654	-6,856	-33.2%			<b>18,000</b>	26,934	-8,934	-33.2%		
Japan	<b>7,459</b>	12,766	-5,306	-41.6%			<b>10,000</b>	16,542	-6,542	-39.6%		
Asia	<b>2,624</b>	2,713	-89	-3.3%			<b>3,300</b>	3,702	-402	-10.9%		
Americas	<b>2,419</b>	4,139	-1,720	-41.6%			<b>3,200</b>	5,238	-2,038	-38.9%		
Europe	<b>1,294</b>	1,034	+260	+25.2%			<b>1,500</b>	1,450	+49	+3.4%		
Total	<b>99,448</b>	100,964	-1,516	-1.5%			<b>134,000</b>	144,283	-10,283	-7.1%		



#### 4. Consolidated Financial Results (Quarterly Comparison)

	12/2008				12/2007			
	1Q Result	2Q Result	3Q Result	4Q Estimate	1Q Result	2Q Result	3Q Result	4Q Result
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Net Sales	30,955	33,751	34,740	34,551	34,114	34,181	32,668	43,318
Operating Income	2,105	2,568	3,486	2,838	4,205	3,663	3,662	4,997
<i>Operating Income Ratio</i>	<i>6.8%</i>	<i>7.6%</i>	<i>10.0%</i>	<i>8.2%</i>	<i>12.3%</i>	<i>10.7%</i>	<i>11.2%</i>	<i>11.5%</i>
Ordinary Income	1,886	2,624	3,176	2,812	4,107	3,747	3,410	4,683
<i>Ordinary Income Ratio</i>	<i>6.1%</i>	<i>7.8%</i>	<i>9.1%</i>	<i>8.1%</i>	<i>12.0%</i>	<i>11.0%</i>	<i>10.4%</i>	<i>10.8%</i>
Net Income	1,001	1,599	2,163	1,535	1,848	1,459	2,059	3,322
<i>Net Income Ratio</i>	<i>3.2%</i>	<i>4.7%</i>	<i>6.2%</i>	<i>4.4%</i>	<i>5.4%</i>	<i>4.3%</i>	<i>6.3%</i>	<i>7.7%</i>
US\$	105.25	104.53	107.74	94.48	119.45	120.85	117.93	113.17
Euro	157.63	163.59	162.20	124.58	156.46	162.90	161.93	163.95

#### 5. Consolidated Segment Results (Quarterly Comparison)

	12/2008				12/2007			
	1Q Result	2Q Result	3Q Result	4Q Estimate	1Q Result	2Q Result	3Q Result	4Q Result
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Net Sales	11,305	12,837	14,314	14,542	10,714	11,142	11,365	18,252
Automotive	9,152	9,818	9,366	9,662	10,118	9,421	9,014	11,483
Analytical	5,913	6,384	6,557	6,144	5,999	6,471	6,062	7,302
Medical	4,583	4,711	4,503	4,201	7,281	7,146	6,225	6,279
Semiconductor	30,955	33,751	34,740	34,551	34,114	34,181	32,668	43,318
Total								
Operating Income	1,231	1,304	2,487	1,675	1,189	1,042	1,873	2,652
Automotive	271	601	473	653	1,060	368	410	833
Analytical	-58	162	321	474	143	439	236	412
Medical	660	499	204	35	1,812	1,813	1,142	1,100
Semiconductor	2,105	2,568	3,486	2,838	4,205	3,663	3,662	4,997
Total								

#### 6. Consolidated Orders and Backlog Information (Quarterly Comparison)

	12/2008				12/2007			
	1Q Result	2Q Result	3Q Result	4Q Estimate	1Q Result	2Q Result	3Q Result	4Q Result
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Orders	12,070	12,287	16,570	-	18,038	11,870	15,096	12,318
Automotive	10,740	10,270	11,082	-	10,115	9,348	10,155	11,043
Analytical	6,213	6,815	6,296	-	5,944	6,606	6,248	6,796
Medical	5,244	4,578	4,472	-	7,964	6,761	5,851	5,621
Semiconductor	34,269	33,952	38,421	-	42,063	34,586	37,351	35,780
Total								
Backlog	27,533	26,983	29,240	-	28,244	28,972	32,702	26,768
Automotive	10,623	11,075	12,791	-	8,406	8,333	9,475	9,035
Analytical	2,385	2,817	2,556	-	2,271	2,407	2,592	2,086
Medical	1,879	1,746	1,715	-	2,636	2,250	1,876	1,218
Semiconductor	42,422	42,622	46,304	-	41,558	41,964	46,646	39,108
Total								

#### 7. Capital expenditures, Depreciation and Research and Development Expenses

	12/2008		12/2007	
	3Q Result	Full-year Estimate	3Q Result	Full-year Result
	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Capital Expenditures (*)	4,572	7,000	7,549	9,336
Depreciation	3,676	4,800	2,858	4,161
R&D Expenses	7,857	10,000	6,724	9,473

(\*) Capital expenditures are investments in tangible and intangible fixed assets.

#### Contact

Nobuhiro Tanji, Corporate Strategy Office, HORIBA, Ltd.  
2, Miyanohigashi-cho, Kisshoin, Minami-ku, Kyoto 601-8510, Japan  
E-mail: nobuhiro.tanji@horiba.com